Activated Platelets Upregulate β₂ Integrin Mac-1 (CD11b/CD18) on Dendritic Cells, Which Mediates Heterotypic...

Area of Science:

• Immunology
• Hematology
• Cell Biology

Background:

• Platelet-dendritic cell (DC) interactions are increasingly recognized.
• The molecular mechanisms governing this cellular cross-talk remain largely undefined.

Purpose of the Study:

• To elucidate the molecular basis of platelet-dendritic cell (DC) interactions.
• To investigate the role of integrin Mac-1 on DCs and glycoprotein (GP) Ibα on platelets in mediating this cross-talk.

Main Methods:

• Dynamic coincubation models using human platelets and monocyte-derived DCs.
• Inhibition studies using antibodies against CD11b and GPIbα.
• Analysis of platelets from Glanzmann thrombasthenia patients and genetically modified mouse models (GPIbα^-/-, IL4R-GPIbα-tg, muMac1).
• In vivo studies assessing DC adhesion to injured arterial walls.
• Investigation of signaling pathways (Akt) and molecular players (P-selectin, P-selectin glycoprotein ligand 1) involved in Mac-1 upregulation.

Main Results:

• Platelet activation significantly enhances DC adhesion to platelets.
• Inhibition or genetic deletion of CD11b or GPIbα markedly reduces DC adhesion to platelets in vitro and in vivo.
• Intravascular anti-CD11b treatment specifically inhibited DC recruitment to injured arteries.
• Activated platelets induce CD11b upregulation on DCs via a pathway involving Akt, P-selectin, and P-selectin glycoprotein ligand 1.
• Targeting the GPIbα-Mac-1 interaction blocked DC-platelet interactions.

Conclusions:

• The GPIbα-Mac-1 axis is a critical mediator of platelet-DC cross-talk.
• Activated platelets enhance DC recruitment through GPIbα-Mac-1 interactions.
• This interaction, involving P-selectin glycoprotein ligand 1, represents a potential therapeutic target for inflammatory and thrombotic conditions.